Latest News and Press Releases

Longeveron hosting partnering discussions for its Alzheimer's disease stem cell therapy program at Cell & Gene Meeting on the Mesa.

Longeveron BOD appoints Interim CEO and Executive Chairman of BOD. Board plans to conduct a national search to identify a permanent CEO.

Longeveron will present and host investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025.

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated...

Longeveron announces closing of up to $17.5 million public offering. Proceeds to support potential BLA readiness activities, among other items.

Longeveron announces the pricing of a public offering of common stock and warrants.

Longeveron will report Q2 2025 financial results and provide a business update on Wednesday, August 13, 2025 after the U.S. financial markets close.

Longeveron licenses patented stem cell technology from the University of Miami.

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Than Powell appointed as Longeveron CBO to lead overall business strategy, Alzheimer's program partnering and HLHS program international strategy.